Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly and Company is asking shareholders to vote on directors, executive pay, auditor ratification, and key governance changes at its 2026 virtual annual meeting. Management seeks approval to declassify the board, remove supermajority voting provisions, and opposes shareholder proposals on an independent chair and expanded lobbying disclosure.
The proxy highlights 2025 revenue of $65.2 billion, reported EPS of $22.95 and non-GAAP EPS of $24.21, along with a 40% 2025 total shareholder return that exceeded the S&P 500 and a peer group over one-, three-, and five-year periods. Incentive plans paid above target, with a 218% annual bonus payout and 200% payouts on three-year shareholder value and relative value awards, reflecting strong stock performance.
ELI LILLY & Co director Gabrielle Sulzberger reported a small stock-based compensation grant. She acquired 5.013 shares of common stock on March 16, 2026 at a price of $989.12 per share through a grant or award rather than an open-market purchase.
According to the disclosure, she elected to defer these shares as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after she separates from service. Following this grant, she directly holds a total of 2,976.209 shares of Eli Lilly common stock.
Eli Lilly & Co director Juan R. Luciano received a stock-based compensation award rather than cash fees. On 2026-03-16, he acquired 16.092 shares of common stock at $989.12 per share as a grant or award. Following this transaction, he directly holds 16,817.420 shares of Eli Lilly common stock.
According to the company’s directors’ deferral plan, these shares have been deferred as stock units in lieu of cash compensation and will be settled in actual shares of common stock after Luciano separates from service as a director.
ELI LILLY & Co director J. Erik Fyrwald reported a small stock-based compensation grant. He acquired 10.026 shares of common stock valued at $989.12 per share, increasing his direct holdings to 75,258.776 shares.
The filing notes he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in Eli Lilly common stock after he separates from board service. This is a routine director compensation transaction rather than an open-market purchase or sale.
Eli Lilly & Co director Ralph Alvarez reported an automatic stock-based compensation grant. On March 16, 2026, he acquired 12.553 shares of common stock at $989.12 per share as a grant or award, increasing his directly held position to 55,601.215 shares.
According to the company’s directors’ deferral plan, Alvarez elected to defer this award as stock units instead of cash compensation, to be settled in common shares after he leaves the board. The filing also shows an indirect holding of 758 shares held by a trust, for which he disclaims beneficial ownership beyond his economic interest.
Eli Lilly and Company is asking shareholders to vote at the 2026 virtual annual meeting on four director nominees, advisory approval of executive compensation, ratification of Ernst & Young LLP as auditor, and amendments to eliminate the classified board and supermajority voting provisions.
The proxy highlights 2025 results: $65.2 billion revenue, $22.95 GAAP EPS, 40% 2025 total shareholder return, progress on obesity and other clinical programs, record manufacturing investments, and continued sustainability commitments (approximately 80% renewable electricity in 2025). The board recommends FOR Items 1–5 and recommends AGAINST two shareholder proposals.
Eli Lilly & Co executive Eric Dozier reported a bona fide gift of 481 shares of common stock. The gift was recorded at no stated price per share and is classified as a non-derivative disposition. After the gift, he holds 14,455.212 shares directly and 385.020 shares indirectly through a 401(k) plan.
ELI LILLY & Co director Gabrielle Sulzberger reported an equity award under the company’s director compensation program. On the reported date, she acquired 4.786 shares of common stock at a reference price of $1,036.05 per share through a grant or award transaction.
According to the footnote, she elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in common shares after she separates from service. Following this award, her directly held common stock balance reported in this filing is 2,966.222 shares.
ELI LILLY & Co director Juan R. Luciano reported an acquisition of 15.363 shares of common stock at $1,036.05 per share through a grant or award. At his election, this compensation was deferred into stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following this award, he directly owns 16,772.019 shares of common stock.
ELI LILLY & Co director J. Erik Fyrwald reported an equity award tied to his board compensation. On the reported date, he acquired 9.572 shares of common stock at a reference price of $1,036.05 per share, bringing his directly held total to 75,120.322 shares. According to the disclosure, he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in shares of common stock after he separates from board service.